LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.

    Reuken, Philipp A / Stallmach, Andreas / Pletz, Mathias W / Brandt, Christian / Andreas, Nico / Hahnfeld, Sabine / Löffler, Bettina / Baumgart, Sabine / Kamradt, Thomas / Bauer, Michael

    Leukemia

    2021  Volume 35, Issue 3, Page(s) 920–923

    MeSH term(s) COVID-19/complications ; Female ; Humans ; Immunocompromised Host ; Lymphoma, Follicular/complications ; Middle Aged ; Recurrence
    Language English
    Publishing date 2021-02-19
    Publishing country England
    Document type Case Reports ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-021-01175-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.

    Mikulska, Malgorzata / Sepulcri, Chiara / Dentone, Chiara / Magne, Federica / Balletto, Elisa / Baldi, Federico / Labate, Laura / Russo, Chiara / Mirabella, Michele / Magnasco, Laura / Di Grazia, Carmen / Ghiggi, Chiara / Raiola, Anna Maria / Giacobbe, Daniele Roberto / Vena, Antonio / Beltramini, Sabrina / Bruzzone, Bianca / Lemoli, Roberto M / Angelucci, Emanuele /
    Bassetti, Matteo

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2023  Volume 77, Issue 2, Page(s) 280–286

    Abstract: ... negative Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] swab) and virological and clinical ... all immunocompromised patients with prolonged/relapsed COVID-19 treated with combination therapy with 2 antivirals (remdesivir ... response (alive, asymptomatic, with negative SARS-CoV-2 swab) at day 30 and the last follow-up.: Results ...

    Abstract Background: Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We aimed to evaluate efficacy and safety of combination treatment in immunocompromised COVID-19 patients.
    Methods: We included all immunocompromised patients with prolonged/relapsed COVID-19 treated with combination therapy with 2 antivirals (remdesivir plus nirmatrelvir/ritonavir, or molnupiravir in case of renal failure) plus, if available, anti-spike monoclonal antibodies (mAbs), between February and October 2022. The main outcomes were virological response at day 14 (negative Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] swab) and virological and clinical response (alive, asymptomatic, with negative SARS-CoV-2 swab) at day 30 and the last follow-up.
    Results: Overall, 22 patients (Omicron variant in 17/18) were included: 18 received full combination of 2 antivirals and mAbs and 4 received 2 antivirals only; in 20 of 22 (91%) patients, 2 antivirals were nirmatrelvir/ritonavir plus remdesivir. Nineteen (86%) patients had hematological malignancy, and 15 (68%) had received anti-CD20 therapy. All were symptomatic; 8 (36%) required oxygen. Four patients received a second course of combination treatment. The response rate at day 14, day 30, and last follow-up was 75% (15/20 evaluable), 73% (16/22), and 82% (18/22), respectively. Day 14 and 30 response rates were significantly higher when combination therapy included mAbs. Higher number of vaccine doses was associated with better final outcome. Two patients (9%) developed severe side effects (bradycardia leading to remdesivir discontinuation and myocardial infarction).
    Conclusions: Combination therapy including 2 antivirals (mainly remdesivir and nirmatrelvir/ritonavir) and mAbs was associated with high rate of virological and clinical response in immunocompromised patients with prolonged/relapsed COVID-19.
    MeSH term(s) Drug Therapy, Combination ; Immunocompromised Host ; Antiviral Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; COVID-19 ; COVID-19 Drug Treatment/adverse effects ; COVID-19 Drug Treatment/methods ; Recurrence ; Humans ; Male ; Female ; Middle Aged ; Aged ; Drug Combinations ; Antibodies, Neutralizing/therapeutic use ; Treatment Outcome
    Chemical Substances Antiviral Agents ; Antibodies, Monoclonal ; cilgavimab and tixagevimab drug combination ; Drug Combinations ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-03-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Severe acute respiratory syndrome coronavirus-2 Alpha variant (B.1.1.7), original wild-type severe acute respiratory syndrome coronavirus 2, and cytomegalovirus co-infection in a young adult with acute lymphoblastic leukemia, case report, and review of the possible cytomegalovirus reactivation mechanisms.

    Amanati, Ali / Shahriari, Mahdi / Bordbar, Mohammad Reza / Hedayati, Seyyed Bozorgmehr / Ziyaeyan, Mazyar / Jamalidoust, Marzieh / Kalani, Mehdi / Heydari Marandi, Nahid

    Journal of medical case reports

    2023  Volume 17, Issue 1, Page(s) 66

    Abstract: Background: Like other viral infections, severe acute respiratory syndrome coronavirus-2 infection ... challenges. Patients who are immunocompromised may co-infect with multiple severe ... for the first time. Remdesivir and valganciclovir were administrated due to persistent enteritis and evidence ...

    Abstract Background: Like other viral infections, severe acute respiratory syndrome coronavirus-2 infection could affect different human body systems, including host immune responses. Three years after its pandemic, we learn more about this novel coronavirus. As we expected, different co-infections with various organisms, such as viruses, bacteria, and even fungi, have been reported. However, concurrent infection with two severe acute respiratory syndrome coronavirus-2 strains and cytomegalovirus is extremely unusual. We have only a rudimentary understanding of such co-infections and their long-term consequences for patients with cancer.
    Case presentation: An 18-year-old young Iranian adult with acute lymphoblastic leukemia presented with abdominal pain, diarrhea, nausea, and vomiting following a recent history of severe acute respiratory syndrome coronavirus-2 infection. The patient never experienced respiratory symptoms, and the chest imaging study was normal on admission. His primary laboratory investigation revealed prerenal azotemia and severe abnormal liver function tests (blood urea nitrogen 32 mg/dL, creatinine 1.75 mg/dL, prothrombin time 66 s, partial thromboplastin time 44.5 s, international normalized ratio 5.14, total bilirubin 2.9 mg/dL, and direct bilirubin 2.59 mg/dL). Cytomegalovirus disease was diagnosed by polymerase chain reaction in his blood and stool samples. The patient's gastrointestinal signs and symptoms improved shortly after receiving intravenous ganciclovir treatment. His gastrointestinal symptoms continued intermittently for weeks despite maintenance valganciclovir prescription, necessitating frequent hospitalizations. The patient was complicated by the recurrence of gastrointestinal symptoms during the sixth hospitalization, even though he had no respiratory symptoms, and the nasopharyngeal test revealed severe acute respiratory syndrome coronavirus-2 Wuhan strain for the first time. Remdesivir and valganciclovir were administrated due to persistent enteritis and evidence of intestinal tissue invasion by severe acute respiratory syndrome coronavirus 2 and cytomegalovirus on multiple intestinal biopsies, which led to partial clinical responses. Cytomegalovirus and severe acute respiratory syndrome coronavirus-2 fecal shedding continued for more than 6 months despite repeated antiviral therapy, and the Wuhan and Alpha strains were also detected in his nasopharyngeal samples through repeated sampling (confirmed by four nasopharyngeal sampling and multiple stool specimens and several intestinal biopsies). Finally, during the Delta-variant (B.1.617.2) outbreak in Iran, the patient was admitted again with febrile neutropenia and decreased level of consciousness, necessitating respiratory support and mechanical ventilation. During the Delta-variant peak, the patient's nasopharyngeal sample once more tested positive for severe acute respiratory syndrome coronavirus 2. The patient died a few days later from cardiopulmonary arrest.
    Conclusion: The coronavirus disease 2019 pandemic has encountered patients with cancer with critical diagnostic and treatment challenges. Patients who are immunocompromised may co-infect with multiple severe acute respiratory syndrome coronavirus-2 strains and cytomegalovirus, and even with timely diagnosis and treatment, the prognosis may be poor.
    MeSH term(s) Male ; Humans ; Young Adult ; Adolescent ; SARS-CoV-2 ; COVID-19 ; Cytomegalovirus ; Coinfection ; Valganciclovir ; Iran ; Cytomegalovirus Infections/complications ; Cytomegalovirus Infections/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
    Chemical Substances Valganciclovir (GCU97FKN3R)
    Language English
    Publishing date 2023-02-10
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2269805-X
    ISSN 1752-1947 ; 1752-1947
    ISSN (online) 1752-1947
    ISSN 1752-1947
    DOI 10.1186/s13256-022-03750-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection

    Reuken, Philipp A. / Pletz, Mathias / Brandt, Christian

    http://lobid.org/resources/99370672770606441#!, 35(3):920-923

    2021  

    Keywords COVID-19 ; COVID-19/complications [MeSH] ; Correspondence ; Female [MeSH] ; Humans [MeSH] ; Immunocompromised Host [MeSH] ; Infectious diseases ; Lymphoma ; Lymphoma, Follicular/complications [MeSH] ; Middle Aged [MeSH] ; Recurrence [MeSH]
    Language English
    Document type Article
    Database Repository for Life Sciences

    More links

    Kategorien

To top